Raji Shameem, MD

Frontline HER2-positive gastric cancer trials test T-DXd combos and TIGIT/PD-L1 bispecifics, aiming to improve survival beyond trastuzumab.

Experts weigh T‑DXd as second-line HER2+ gastric cancer therapy, stressing rebiopsy/ctDNA and vigilant pneumonitis risk.

Experts weigh T‑DXd for HER2+ gastric cancer after prior therapy, stressing rebiopsy or ctDNA confirmation and vigilant pneumonitis monitoring.

Clinicians share real-world tips to prevent and manage zanidatamab-related diarrhea, using early loperamide, patient counseling, follow-up calls, and supportive care.

CLL therapy evolves fast: frontline trial updates, pirtobrutinib in second line, and BTK degraders promise simpler, better-tolerated options.

Experts weigh using triplet immunotherapy plus chemo for PD‑L1–negative patients, balancing survival gains, side effects, and FDA approval in first-line care.

New trial updates tease stronger survival with zanidatumab combos; two analyses ahead may clarify OS, biomarkers, and tislelizumab’s added value.

A 72-year-old CLL patient stops covalent BTK therapy due to AFib and hypertension; experts weigh switching BTK agents, pirtobrutinib, or venetoclax.

Phase 3 data show pirtobrutinib extends PFS and delays next therapy after BTK inhibitors, with low atrial fibrillation and hypertension rates.

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

HORIZON GEA 01 shows zanidatamab regimens significantly improve survival in HER2-positive gastric, esophageal, and GEJ cancer, while PD-L1 testing differences raise key questions for treatment choice.

Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.

Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.

Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.

Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.

Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.

Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.

Experts unpack zanidatamab’s dual HER2 binding, why JACOB nearly succeeds, and what standout gastric and biliary cancer responses mean next.

Clinicians explain zanidatamab’s action and HORIZON-GEA-01

Raji Shameem, MD, discusses first-line treatment planning for pancreatic adenocarcinoma including clinical trial eligibility alongside standard chemotherapy options.

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.